

## Ropinirole-Induced Anterocollis in Parkinson's Disease

Lucia Ameghino, MD,<sup>1</sup> Malco Rossi, MD,<sup>1</sup> Ángel Cammarota, MD,<sup>1</sup> Marcelo Merello, MD, PhD<sup>1,2,\*</sup>

Anterocollis or antecollis, also called dropped head, is characterized by disproportionate flexion of the head over the trunk and can result from either muscle weakness (i.e., myasthenia gravis and motor neuron disease) or muscle hyperactivity in cases of dystonia.<sup>1</sup> Anterocollis has been described in patients with Parkinson's disease (PD) or multiple system atrophy; however, it is still debated whether, in these cases, it is dystonic in nature or myopathic or both.<sup>2,3</sup> Anterocollis has also been described with use of antiparkinsonian medications, such as amantadine and certain dopamine agonists (DAs; cabergoline, pramipexole, or rotigotine).<sup>2-7</sup> We report here videotape evidence of anterocollis development secondary to ropinirole use, with full recovery after drug discontinuation.

### Case Presentation

A 76-year-old man referred mood changes and apathy developing during the last 10 years. Soon after, he began to experience difficulty walking, needing to take shorter steps, and also referred clumsiness when using his hands. At the initial consultation, the patient referred symptoms consistent with rapid eye movement sleep behavior disorder, olfactory impairment, and chronic constipation as well as progressive immobilization. On the other hand, he denied urinary incontinence or syncope. After the diagnosis of PD was confirmed, he started levodopa four times a day. Symptoms progressed over a 10-year period with evident cognitive impairment in the last 2 years. The patient was treated with 675 mg of an L-dopa/carbidopa combination on a three times daily basis, along with 30 mg of duloxetine and 5 mg of donepezil daily, and 4 mg of extended-release ropinirole. On physical examination, 2 hours after his usual L-dopa dose, his International Parkinson and Movement Disorder Society/UPDRS Part III score was of 31 points. At the same time, his H & Y was 3 and Mini-Mental State Examination score was 27/30. The patient presented no "red flags" for atypical parkinsonism.

Last year, the patient developed a peptic ulcer, which required admission to the intensive care unit for 16 days. He developed transient delirium during his hospitalization and was treated with clozapine. Ropinirole, however, had to be withdrawn in order

to resolve psychotic symptoms. One month later, clozapine was discontinued and ropinirole was progressively reintroduced with an initial dose of 8 mg and then increased to 12 mg. Two weeks after starting the 12-mg dose, he developed progressive anterocollis and slight camptocormia (see Video 1, left panel), to a degree in which his chin fell down and came into contact with his chest. Both active and passive mobilization of the neck was difficult. A simultaneous surface electromyography (EMG) was performed on the neck muscles, at rest (for 1 minute), during head rotation, tilt to either side, and during head flexion and extension. Both sternocleidomastoid and trapezius muscles showed signs of cocontraction. No signs of fasciculation or denervation were found in either muscle. Routine lab workup showed normal creatine kinase, aldolase, thyroid hormones, and acetylcholine receptor antibody values. Owing to the rapid symptom onset and the link to ropinirole increase, the drug was withdrawn. Four months after drug discontinuation, anterocollis completely resolved, although the cardinal symptoms of PD significantly deteriorated (see Video 1, right panel).

### Discussion

Although postural disturbances are common in PD, mainly associated with the disease itself, they can also be caused or worsened by medication.<sup>8,9</sup> Despite that DA-induced anterocollis has been previously reported, this is, to our knowledge, the first case associated with ropinirole use, confirming its dystonic nature. Still, 1 case of reversible Pisa syndrome associated with ropinirole in a PD patient has been previously described.<sup>10</sup> Pathophysiology of anterocollis in PD is controversial, given that it is believed to be generated either by disproportionate neck muscle tone of both extensors and flexors, or through dystonia or myopathy of the extensor muscles.<sup>2,3,7</sup> In this case, surface EMG showed cocontraction of extensor and flexor neck muscles without evidence of myopathy, thus favoring a dystonic etiology. Risk factors related to anterocollis and similar dystonic features in PD besides DAs are age, disease duration, dementia, and female gender.<sup>3,8,9</sup> Clinicians treating PD patients should consider DAs as a potential source of anterocollis syndrome.

<sup>1</sup>Movement Disorders Section, Neuroscience Department, Raul Carrea Institute for Neurological Research (FLENI), Buenos Aires, Argentina;

<sup>2</sup>Argentine National Scientific and Technological Research Council (CONICET), Buenos Aires, Argentina

\*Correspondence to: Dr. Marcelo Merello, Movement Disorders Section and Neuroscience Department, Raul Carrea Institute for Neurological Research (FLENI), Montañeses 2325, Ciudad Autónoma de Buenos Aires 1428, Argentina; E-mail: mmerello@fleni.org.ar

**Keywords:** ropinirole, Parkinson's disease, anterocollis, dropped head.

Relevant disclosures and conflicts of interest are listed at the end of this article.

Received 2 March 2015; revised 9 June 2015; accepted 9 June 2015.

Published online 13 November 2015 in Wiley InterScience (www.interscience.wiley.com). DOI:10.1002/mdc3.12218

## Author Roles

(1) Research project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript preparation: A. Writing of the first draft, B. Review and Critique;

L.A.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B

M.R.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B

A.C.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B

M.M.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B

## Acknowledgment

Full consent was obtained from the patient before publication.

## Disclosures

**Funding Sources and Conflicts of Interest:** The authors report no sources of funding and no conflicts of interest.

**Financial Disclosures for previous 12 months:** The authors declare that there are no disclosures to report.

## References

1. Fujimoto K. Dropped head in Parkinson's disease. *J Neurol* 2006;253 (suppl 7):VII21–VII26.
2. Yoshiyama Y, Takama J, Hattori T. The dropped head sign in parkinsonism. *J Neurol Sci* 1999;167:22–25.
3. Suzuki M, Hirai T, Ito Y, Sakamoto T, Oka, H, Kurita, A, Inoue, K. Pramipexole-induced anterocollis in Parkinson's disease. *J Neurol Sci* 2008;264:195–197.
4. Kataoka H, Ueno S. Dropped head associated with amantadine in Parkinson disease. *Clin Neuropharmacol* 2011;34:48–49.
5. Taguchi Y, Takashima S, Tanaka K. Pramipexol-induced dropped head syndrome in Parkinson's disease. *Intern Med* 2008;47:2011–2012.
6. Dohm CP, Gröschel S, Liman J, Bähr M, Kermer P. Dropped head sign induced by transdermal application of the dopamine agonist rotigotine in parkinsonian syndrome: a case report. *J Med Case Rep* 2013;7:174.
7. Savica R, Kumar N, Ashlskog JE, Josephs KA, Matsumoto JY, McKeon A. Parkinsonism and dropped head: dystonia, myopathy or both? *Parkinsonism Relat Disord* 2012;18:30–34.
8. Kashiwara K, Ohno M, Tomita S. Dropped head syndrome in Parkinson's disease. *Mov Disord* 2006;21:1213–1216.
9. Oyama G, Hayashi A, Mizuno Y, Hattori N. Mechanism and treatment of dropped head syndrome associated with parkinsonism. *Parkinsonism Relat Disord* 2009;15:181–186.
10. Galati S, Möller J, Städler C. Ropinirole-induced Pisa syndrome in Parkinson disease. *Clin Neuropharmacol* 2014;37:58–59.

## Supporting Information

A video accompanying this article is available in the supporting information here.

**Video 1.** Left panel: patient under treatment with ropinirole. Notice marked anterocollis and chin leaning on patient's chest. Right panel: patient after 4 months of ropinirole withdrawal, showing complete resolution of anterocollis.